MNOV - MediciNova, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.79
+0.37 (+6.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close5.42
Open6.00
Bid5.08 x 1100
Ask5.80 x 900
Day's Range5.58 - 6.00
52 Week Range2.79 - 10.84
Volume469,012
Avg. Volume168,172
Market Cap255.153M
Beta (5Y Monthly)1.72
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • GlobeNewswire

    MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Investigational New Drug Application (IND) for MN-166 (ibudilast) for prevention of Acute Respiratory Distress Syndrome (ARDS) has been accepted and is now open with the U.S. Food and Drug Administration (FDA). MediciNova was informed by the FDA that the proposed clinical investigation of MN-166 (ibudilast) for the prevention of ARDS in patients with COVID-19 may proceed.

  • GlobeNewswire

    MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive preclinical findings published in Frontiers in Immunology regarding the prospect of MN-166 (ibudilast) as an adjunct treatment for glioblastoma. The publication, entitled “Glioblastoma myeloid-derived suppressor cell subsets express differential macrophage migration inhibitory factor receptor profiles that can be targeted to reduce immune suppression”, was a collaborative effort between MediciNova and the Cleveland Clinic, led by Tyler Alban (doctoral candidate) and Dr. Justin Lathia, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at the Lerner Research Institute, Cleveland Clinic, and Associate Professor, Department of Molecular Medicine at Case Western Reserve University.

  • GlobeNewswire

    MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover a method of reducing a triglyceride blood level, a method of reducing a total cholesterol blood level, and a method of reducing a low-density lipoprotein (LDL) blood level using MN-001 or MN-002.

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma. This new patent has improved therapeutic claims compared to the first patent which covers MN-166 (ibudilast) for the treatment of glioblastoma, which was granted last year, and has a later expiration date than the first patent. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than February 2039.

  • GlobeNewswire

    MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a clinical trial of MN-166 (ibudilast) for acute respiratory distress syndrome (ARDS) caused by COVID-19 (Coronavirus Disease 2019). The study will be conducted by Yale’s Advanced Therapies Group, which is co-directed by Richard Bucala, M.D., Ph.D., Chief, Rheumatology, Allergy & Immunology at Yale School of Medicine and Rheumatologist-in-Chief at Yale New Haven Health.

  • GlobeNewswire

    MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate development of MN-166 (ibudilast) for severe pneumonia and acute respiratory distress syndrome (ARDS). MediciNova’s decision to pursue development of this indication was based on positive results of a recent preclinical study in an animal model of ARDS (Med Sci Monit, 2020; 26: e922281).

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of advanced nonalcoholic steatohepatitis (NASH). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims also cover advanced NASH patients that exhibit hepatic fibrosis, spider angiomata, ascites, splenomegaly, hard liver border, palmar erythema, asterixis, portal hypertension, hepatic scarring, cirrhosis, or hepatocellular carcinoma (HCC).

  • GlobeNewswire

    MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis.

  • GlobeNewswire

    MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of MediciNova’s completed clinical trial of MN-166 (ibudilast) in ALS (amyotrophic lateral sclerosis), which was conducted at Carolinas HealthCare System’s Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute, will be presented on December 5, 2019 at 10:30 am local time at the 30th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) in Perth, Australia.

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of amyotrophic lateral sclerosis (ALS). The allowed claims cover the use of MN-166 (ibudilast) to treat a patient diagnosed with ALS.  The allowed claims cover oral administration in a wide range of daily dosages.  Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2028.

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of idiopathic pulmonary fibrosis (IPF).

  • GlobeNewswire

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Chinese Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of idiopathic pulmonary fibrosis (IPF).

  • GlobeNewswire

    MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 10:30 am at the Sofitel Hotel in New York City.  Management will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market.

  • GlobeNewswire

    MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will attend the Morgan Stanley Global Healthcare Conference which will be held at the Grand Hyatt New York in New York City from September 9 - 11, 2019. Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley. MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market.

  • GlobeNewswire

    MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with the Japanese National Cerebral and Cardiovascular Disease Research Center,  Division of Lipid Metabolism, Department of Molecular Innovation in Lipidology, to evaluate the effects of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, “MN‑001 is a novel orally-administered compound with multiple mechanisms, and its anti-fibrosis and anti-inflammatory effects have been observed in multiple animal models studies.

  • GlobeNewswire

    MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia

    The presentation entitled "Interaction (nonuniformity) of ALS Progression and the Efficacy of MN‑166 (ibudilast)” will be given by Kazuko Matsuda, M.D. Ph.D. M.P.H., Chief Medical Officer, MediciNova, Inc. Presentation details will be disseminated as they become available. “We are very pleased to present additional findings from the completed ALS study at the 30th International Symposium on ALS/MND.

  • GlobeNewswire

    MediciNova Appoints Kazuko Matsuda to its Board of Directors

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Dr. Kazuko Matsuda to its Board of Directors. Dr. Matsuda received her M.D. and Ph.D. from Sapporo Medical School in Japan, and Master of Public Health from Harvard University, School of Public Health, in the U.S. She is a board-certified pediatrician in both the United States and Japan. Dr. Matsuda, in her capacity as Chief Medical Officer for MediciNova since 2013, has demonstrated time and again strong leadership skills and creativity culminating in the advancement of MediciNova’s promising clinical drug development programs.

  • GlobeNewswire

    MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS) following feedback from the FDA (U.S. Food and Drug Administration).